Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Drug Delivery in Paediatric Brain Tumours /
Treating relapsed brain tumours with anti-angiogenic metronomic therapy

1st - 2nd Feb 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.02.16
Views: 2011
Rating:

Dr Irene Slavc - Medical University of Vienna, Vienna, Austria

Dr Slavc talks to ecancertv at Children with Cancer UK’s workshop on Drug Delivery in Paediatric Brain Tumours in London, UK.

In the interview she discusses the use of metronomic anti-angiogenic therapy in patients with relapsed brain tumours.

Together with colleagues in Boston and several other European centres, Dr Slav is conducting a trial in children and young adolescents who have relapsed medulloblastoma.

These patients have a very poor prognosis even when treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or combinations of all these approaches.

The novel treatment regimen being tested in the trial consists of biweekly intravenous bevacizumab in combination with five oral drugs (thalidomide, celecoxib, fenofibrate, and alternating cycles of daily low-dose oral etoposide and cyclophosphamide).

This is augmented with alternating courses of intrathecal etoposide and liposomal cytarabine.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation